Comparison of the prophylactic use of ibandronate and its use in early-stage osteonecrosis in rats with steroid-induced osteonecrosis of the femoral head

被引:1
作者
Caglar, Sever [1 ,5 ]
Dasnci, Mustafa Fatih [1 ]
Acar, Abdurrahman [1 ]
Caglar, Aysel [2 ]
Dincel, Yasar Mahsut [3 ]
Cataltepe, Aziz [4 ]
机构
[1] Hlth Sci Univ, Bagcilar Training & Res Hosp, Dept Orthoped & Traumatol, Istanbul, Turkiye
[2] Hlth Sci Univ, Bagcilar Training & Res Hosp, Dept Med Pathol, Istanbul, Turkiye
[3] Namik Kemal Univ, Fac Med, Dept Orthoped & Traumatol, Tekirdag, Turkiye
[4] Medipol Univ, Dept Orthoped & Traumatol, Istanbul, Turkiye
[5] Bagcilar Egitim & Hastanesi, Ortoped & Travmatol Klin, TR-34200 Istanbul, Turkiye
关键词
Bisphosphonate; femoral head; ibandronate; osteonecrosis; rat; NONTRAUMATIC OSTEONECROSIS; ALENDRONATE; BISPHOSPHONATE; HIP; PREVENTION; COLLAPSE; EFFICACY; RISEDRONATE; FRACTURES; STRENGTH;
D O I
10.52312/jdrs.2023.1096
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Objectives: The aim of this study was to investigate the effects of ibandronate before and after the onset of osteonecrosis in rats with steroid-induced osteonecrosis of the femoral head.Materials and methods: A total of 24 female Sprague-Dawley rats were used in this study. Three groups were formed with eight rats in each group. The first group was the prophylactic group that received ibandronate treatment before and after the onset of osteonecrosis (Group PT). The second group received ibandronate treatment three weeks after the development of osteonecrosis (Group TAO). The third group was the control group in which osteonecrosis was created, but only normal saline (NS) was given. At the end of the study, all rats were sacrificed, and their right femoral heads were removed, fixed with formalin, and sent for micro-computed tomography. Hematoxylin-eosin (H & E) and immunohistochemical examinations of the right femoral head sections were performed.Results: In the PT group, the trabecular thickness was significantly higher compared to those of the TAO and control groups (p<0.05). The trabecular thickness did not significantly differ between the TAO and control groups. The trabecular bone pattern factor was significantly higher in the PT group compared to the control and TAO groups (p<0.05); however, it showed no significant difference between the TAO and control groups. The incidence of type 2 osteonecrosis in the PT and TAO groups was significantly lower than that in the control group (p<0.05). The incidence of tissue-non-specific alkaline phosphatase (TNAPase) immunoreactivity of osteoblast positivity was significantly higher in the PT and TAO groups compared to the control group (p<0.05), whereas the incidence of TRAPase immunoreactivity of osteoclastic positivity was significantly lower in the PT and TAO groups compared to the control group (p<0.05).Conclusion: Intravenous administration of ibandronate before the onset of the disease was more effective in the treatment of osteonecrosis in rats with steroid-induced osteonecrosis of the femoral head.
引用
收藏
页码:640 / 650
页数:11
相关论文
共 35 条
[1]   Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study [J].
Agarwala, S ;
Jain, D ;
Joshi, VR ;
Sule, A .
RHEUMATOLOGY, 2005, 44 (03) :352-359
[2]   Bisphosphonate Combination Therapy in the Management of Postchemotherapy Avascular Necrosis of the Femoral Head in Adolescents and Young Adults: A Retrospective Study From India [J].
Agarwala, Sanjay ;
Banavali, Shripad D. ;
Vijayvargiya, Mayank .
JOURNAL OF GLOBAL ONCOLOGY, 2018, 4 :1-11
[3]   Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: What we think we know and what we know that we don't know [J].
Allen, Matthew R. ;
Burr, David B. .
BONE, 2011, 49 (01) :56-65
[4]   Enoxaparin Prevents Steroid-Related Avascular Necrosis of the Femoral Head [J].
Beckmann, Rainer ;
Shaheen, Hayfaa ;
Kweider, Nisreen ;
Ghassemi, Alireza ;
Fragoulis, Athanassios ;
Hermanns-Sachweh, Benita ;
Pufe, Thomas ;
Kadyrov, Mamed ;
Drescher, Andwolf .
SCIENTIFIC WORLD JOURNAL, 2014,
[5]   Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].
Black, DM ;
Cummings, SR ;
Karpf, DB ;
Cauley, JA ;
Thompson, DE ;
Nevitt, MC ;
Bauer, DC ;
Genant, HK ;
Haskell, WL ;
Marcus, R ;
Ott, SM ;
Torner, JC ;
Quandt, SA ;
Reiss, TF ;
Ensrud, KE .
LANCET, 1996, 348 (9041) :1535-1541
[6]   Ten years' experience with alendronate for osteoporosis in postmenopausal women [J].
Bone, HG ;
Hosking, D ;
Devogelaer, J ;
Tucci, JR ;
Emkey, RD ;
Tonino, RP ;
Rodriguez-Portales, JA ;
Downs, RW ;
Gupta, J ;
Santora, AC ;
Liberman, UA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (12) :1189-1199
[7]   Alendronate in the prevention of collapse of the femoral head in nontraumatic osteonecrosis: A two-year multicenter, prospective, randomized, double-blind, placebo-controlled study [J].
Chen, Chung-Hwan ;
Chang, Je-Ken ;
Lai, Kuo-An ;
Hou, Sheng-Mou ;
Chang, Chih-Hao ;
Wang, Gwo-Jaw .
ARTHRITIS AND RHEUMATISM, 2012, 64 (05) :1572-1578
[8]   Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results [J].
Delmas, P. D. ;
Benhamou, C. L. ;
Man, Z. ;
Tlustochowicz, W. ;
Matzkin, E. ;
Eusebio, R. ;
Zanchetta, J. ;
Olszynski, W. P. ;
Recker, R. R. ;
McClung, M. R. .
OSTEOPOROSIS INTERNATIONAL, 2008, 19 (07) :1039-1045
[9]   Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis [J].
Delmas, Pierre D. ;
McClung, Michael R. ;
Zanchetta, Jose R. ;
Racewicz, Artur ;
Roux, Christian ;
Benhamou, Claude-Laurent ;
Mang, Zulema ;
Eusebio, Rachelle A. ;
Beary, John F. ;
Burgio, David E. ;
Matzkin, Ellen ;
Boonen, Steven .
BONE, 2008, 42 (01) :36-42
[10]   BISPHOSPHONATE THERAPEUTICS IN BONE DISEASE: The Hard and Soft Data on Osteoclast Inhibition [J].
Drake, Matthew T. ;
Cremers, Serge C. L. M. .
MOLECULAR INTERVENTIONS, 2010, 10 (03) :141-152